Defined αβ T cell receptors with distinct ligand specificities do not require those ligands to signal double negative thymocyte differentiation


ERMAN M. B., Guinter T., Singer A.

JOURNAL OF EXPERIMENTAL MEDICINE, cilt.199, sa.12, ss.1719-1724, 2004 (SCI-Expanded) identifier identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 199 Sayı: 12
  • Basım Tarihi: 2004
  • Doi Numarası: 10.1084/jem.20032204
  • Dergi Adı: JOURNAL OF EXPERIMENTAL MEDICINE
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.1719-1724
  • Acıbadem Mehmet Ali Aydınlar Üniversitesi Adresli: Hayır

Özet

During T cell development in the thymus, pre-T cell receptor (TCR,) complexes signal CD4(-)CD8(-) (double negative [DN]) thymocytes to differentiate into CD4(+) CD8(+) (double positive [DP]) thymocytes, and they generate such signals without apparent ligand engagements. Although ligand-independent signaling is unusual and might be unique to the pre-TCR, it is possible that other TCR complexes such as alphabeta TCR or alphagamma TCR might also be able to signal the DN to DP transition in the absence of ligand engagement if they were expressed on DN thymocytes. Although alphagamma TCR complexes efficiently signal DN thymocyte differentiation, it is not yet certain if alphabeta TCR complexes are also capable of signaling DN thymocyte differentiation, nor is it certain if such signaling is dependent upon ligand engagement. This study has addressed these questions by expressing defined alphabeta TCR transgenes in recombination activating gene 2(-/-) pre-Talpha(-/-) double deficient mice. In such double deficient mice, the only antigen receptors that can be expressed are those encoded by the alphabeta TCR transgenes. In this way, this study definitively demonstrates that alphabeta TCR can in fact signal the DN to DP transition. In addition, this study demonstrates that transgenic alphabeta TCRs signal the DN to DP transition even in the absence of their specific MHC-peptide ligands.